HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER-2 Positive Breast Cancer
Interventions: DRUG: T-DM1|PROCEDURE: 89Zr-trastuzumab
Sponsor: Jules Bordet Institute
Collaborators: Roche Pharma AG